Business Description
Infant Bacterial Therapeutics AB
ISIN : SE0008015259
Share Class Description:
IFTBF: Class BCompare
Compare
Traded in other countries / regions
IBT B.Sweden9IB.GermanyIBTBs.UKIFTBF.USA IPO Date
2016-08-02Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.85 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -16.1 | |||||
| 3-Year EPS without NRI Growth Rate | -15.8 | |||||
| 3-Year FCF Growth Rate | -16.3 | |||||
| 3-Year Book Growth Rate | -16.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 72.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.52 | |||||
| Quick Ratio | 6.52 | |||||
| Cash Ratio | 6.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 | |||||
| Shareholder Yield % | -0.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -52.6 | |||||
| ROA % | -44.38 | |||||
| ROIC % | -522 | |||||
| ROCE % | -52.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.7 | |||||
| Price-to-Tangible-Book | 3.87 | |||||
| EV-to-EBIT | -3.67 | |||||
| EV-to-EBITDA | -3.69 | |||||
| EV-to-FCF | -3.72 | |||||
| Price-to-Net-Current-Asset-Value | 3.87 | |||||
| Price-to-Net-Cash | 3.96 | |||||
| Earnings Yield (Greenblatt) % | -27.25 | |||||
| FCF Yield % | -18.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with GREY:IFTBF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Infant Bacterial Therapeutics AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.038 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 72.22 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 8.2 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 7.47 - 8.38 | ||
| Shares Outstanding (Mil) | 13.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Infant Bacterial Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Infant Bacterial Therapeutics AB Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Infant Bacterial Therapeutics AB Frequently Asked Questions
What is Infant Bacterial Therapeutics AB(IFTBF)'s stock price today?
The current price of IFTBF is $8.20. The 52 week high of IFTBF is $8.38 and 52 week low is $7.47.
When is next earnings date of Infant Bacterial Therapeutics AB(IFTBF)?
The next earnings date of Infant Bacterial Therapeutics AB(IFTBF) is 2025-02-07 Est..
Does Infant Bacterial Therapeutics AB(IFTBF) pay dividends? If so, how much?
Infant Bacterial Therapeutics AB(IFTBF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers